Literature DB >> 21914461

EGF and angiotensin II modulate lysophosphatidic acid LPA(1) receptor function and phosphorylation state.

Christian C Colín-Santana1, S Eréndira Avendaño-Vázquez, Rocío Alcántara-Hernández, J Adolfo García-Sáinz.   

Abstract

BACKGROUND: Lysophosphatidic acid (LPA) is a local mediator that exerts its actions through G protein coupled receptors. Knowledge on the regulation of such receptors is scarce to date. Here we show that bidirectional cross-talk exits between LPA(1) and EGF receptors.
METHODS: C9 cells expressing LPA(1) receptor fussed to the enhanced green fluorescent protein were used. We studied intracellular calcium concentration, Akt/PKB phosphorylation, LPA(1) and EGF receptor phosphorylation.
RESULTS: EGF diminished LPA-mediated intracellular calcium response and induced LPA(1) receptor phosphorylation, which was sensitive to protein kinase C inhibitors. Angiotensin II and LPA induced EGF receptor transactivation as evidenced by Akt/PKB phosphorylation through metalloproteinase-catalyzed membrane shedding of heparin-binding EGF and autocrine/paracrine activation of EGF receptors. This process was found to be of major importance in angiotensin II-induced LPA(1) receptor phosphorylation. Attempts to define a role for EGF receptor transactivation in homologous LPA(1) receptor desensitization and phosphorylation suggested that G protein-coupled receptor kinases are the major players in this process, overshadowing other events.
CONCLUSIONS: EGF receptors and LPA(1) receptors are engaged in an intense liaison, in that EGF receptors are capable of modulating LPA(1) receptor function through phosphorylation cascades. EGF transactivation plays a dual role: it mediates some LPA actions, and it modulates LPA(1) receptor function in inhibitory fashion. GENERAL SIGNIFICANCE: EGF and LPA receptors coexist in many cell types and play key roles in maintaining the delicate equilibrium that we call health and in the pathogenesis of many diseases. The intense cross-talk described here has important physiological and pathophysiological implications. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21914461     DOI: 10.1016/j.bbagen.2011.08.016

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer.

Authors:  Qingchun Cai; Zhenwen Zhao; Caryl Antalis; Libo Yan; Giuseppe Del Priore; Ali Hassan Hamed; Frederick B Stehman; Jeanne M Schilder; Yan Xu
Journal:  FASEB J       Date:  2012-07-05       Impact factor: 5.191

Review 2.  Molecular Regulation of Lysophosphatidic Acid Receptor 1 Maturation and Desensitization.

Authors:  Jing Zhao; Thomas Stephens; Yutong Zhao
Journal:  Cell Biochem Biophys       Date:  2021-05-25       Impact factor: 2.194

3.  α1B-adrenergic receptors differentially associate with Rab proteins during homologous and heterologous desensitization.

Authors:  Jean A Castillo-Badillo; Omar B Sánchez-Reyes; Marco A Alfonzo-Méndez; M Teresa Romero-Ávila; Guadalupe Reyes-Cruz; J Adolfo García-Sáinz
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA1, LPA2, and LPA3.

Authors:  Rocío Alcántara-Hernández; Aurelio Hernández-Méndez; Gisselle A Campos-Martínez; Aldo Meizoso-Huesca; J Adolfo García-Sáinz
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

5.  Eicosopentaneoic Acid and Other Free Fatty Acid Receptor Agonists Inhibit Lysophosphatidic Acid- and Epidermal Growth Factor-Induced Proliferation of Human Breast Cancer Cells.

Authors:  Mandi M Hopkins; Zhihong Zhang; Ze Liu; Kathryn E Meier
Journal:  J Clin Med       Date:  2016-01-26       Impact factor: 4.241

Review 6.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.